Dehydrocorydaline chloride

• CAT Number: I000306
• CAS Number: 10605-03-5
• Molecular Formula: C22H24ClNO4
• Molecular Weight: 401.88
• Purity: ≥95%
• Target: Bcl-2 Family; Caspase; PARP; p38 MAPK; Parasite; Autophagy
• Solubility: DMSO
• Storage: 3 years -20C powder

Dehydrocorydaline chloride (CAT: I000306) is an alkaloid compound with demonstrated anti-inflammatory and anti-cancer activities. In vitro, studies have shown that Dehydrocorydaline chloride promotes myoblast differentiation by increasing the expression of muscle-specific proteins and activating p38 MAPK signaling. It also exhibits anti-proliferative effects on MCF-7 breast cancer cells by inducing apoptosis through modulation of the Bax/Bcl-2 pathway and activation of caspases. In vivo, Dehydrocorydaline chloride demonstrates dose-dependent antinociceptive effects in pain models, reducing the expression of pro-inflammatory proteins in the spinal cord. These findings suggest the potential pharmacological applications of Dehydrocorydaline chloride in muscle regeneration, cancer therapy, and pain management.

Reference

[1]. Yoo M, et al. Dehydrocorydaline promotes myogenic differentiation via p38 MAPK activation. Mol Med Rep. 2016 Oct;14(4):3029-36.

[2]. Yin ZY, et al. Antinociceptive effects of dehydrocorydaline in mouse models of inflammatory pain involve the opioid receptor and inflammatory cytokines. Sci Rep. 2016 Jun 7;6:27129.

[3]. Xu Z, et al. Dehydrocorydaline inhibits breast cancer cells proliferation by inducing apoptosis in MCF-7 cells. Am J Chin Med. 2012;40(1):177-85.

[4]. Dou Z, et al. Effect of wine and vinegar processing of Rhizoma Corydalis on the tissue distribution of tetrahydropalmatine, protopine and dehydrocorydaline in rats. Molecules. 2012 Jan 18;17(1):951-70.

[5]. Matsuda H, et al. Inhibitory effects of dehydrocorydaline isolated from Corydalis Tuber against type I-IV allergic models. Biol Pharm Bull. 1997 Apr;20(4):431-4.